Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127383141 | 12738314 | 1 | I | 20160907 | 20160913 | 20160913 | PER | US-PFIZER INC-2016423184 | PFIZER | 68.00 | YR | F | Y | 0.00000 | 20160913 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127383141 | 12738314 | 1 | PS | NEURONTIN | GABAPENTIN | 1 | Oral | 300MG CAPSULES; 2 CAPSULES BY MOUTH DAILY AND THREE CAPSULES AT BEDTIME | 20235 | 1500 | MG | CAPSULE, HARD | |||||||
| 127383141 | 12738314 | 2 | SS | VALTREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 1 G, 3X/DAY | 0 | 1 | G | TABLET | TID | ||||||
| 127383141 | 12738314 | 3 | SS | HYDROCODONE | HYDROCODONE | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127383141 | 12738314 | 1 | Herpes zoster |
| 127383141 | 12738314 | 2 | Herpes zoster |
| 127383141 | 12738314 | 3 | Herpes zoster |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127383141 | 12738314 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |